Investment Thesis
ACAD demonstrates strong operational fundamentals with exceptional profitability (36.5% net margin, 31.9% ROE) and healthy revenue growth of 11.9% YoY, driven by pharmaceutical operations in a stable sector. The company maintains a fortress balance sheet with minimal debt (0.0x D/E), strong liquidity (3.83x current ratio), and positive free cash flow generation of $105.1M, providing financial flexibility for R&D investments and shareholder returns.
ACAD Strengths
- Exceptional net profitability with 36.5% net margin and 31.9% ROE indicating efficient capital deployment
- Strong balance sheet with zero long-term debt and $177.7M cash position relative to $1.6B total assets
- Robust liquidity position with 3.83x current ratio and 3.43x quick ratio providing operational flexibility
- Positive free cash flow generation of $105.1M with 9.8% FCF margin supporting sustainability
- Revenue growth of 11.9% YoY in pharmaceutical sector demonstrates market demand and product traction
ACAD Risks
- Operating margin of 9.8% is significantly lower than net margin of 36.5%, suggesting potential operational leverage concerns or non-operating income reliance
- Net income flat YoY (0.0% growth) despite 11.9% revenue growth indicates margin compression or increased expenses that warrant investigation
- Capital intensity appears low ($4.7M capex) which may constrain long-term competitiveness in R&D-dependent pharmaceutical sector
- 7 Form 4 filings in last 90 days suggests elevated insider trading activity that warrants monitoring for potential concerns
Key Metrics to Watch
- Operating margin trend and cost structure evolution relative to gross margin stability
- Net income growth acceleration to support revenue growth rate
- Research and development spending levels as percentage of revenue to ensure competitive R&D investment
- Free cash flow sustainability and deployment strategy (R&D, acquisitions, or capital returns)
- Gross margin maintenance amid potential pricing pressures or product mix changes
ACAD Financial Metrics
Revenue
$1.1B
Net Income
$391.0M
EPS (Diluted)
$2.30
Free Cash Flow
$105.1M
Total Assets
$1.6B
Cash Position
$177.7M
ACAD Profitability Ratios
Gross Margin
63.9%
Operating Margin
9.8%
Net Margin
36.5%
ROE
31.9%
ROA
25.0%
FCF Margin
9.8%
ACAD Balance Sheet & Liquidity
Current Ratio
3.83x
Quick Ratio
3.43x
Debt/Equity
0.00x
Debt/Assets
21.5%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by Claude AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: Mar 19, 2026 |
Data as of: 2025-12-31 |
Powered by Claude AI